Verrica Pharmaceuticals
VRCA
74 hedge funds and large institutions have $136M invested in Verrica Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 9 closing their positions.
621% more call options, than puts
Call options by funds: $584K | Put options by funds: $81K
156% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 9
29% more capital invested
Capital invested by funds: $105M → $136M (+$30.8M)
23% more funds holding
Funds holding: 60 → 74 (+14)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0.21% more ownership
Funds ownership: 4.18% → 4.4% (+0.21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$3.26M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$3.25M |
| 3 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$2.15M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$542K |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$384K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.08M |
| 2 |
Morgan Stanley
New York
|
-$379K |
| 3 |
MMA
Miracle Mile Advisors
Los Angeles,
California
|
-$263K |
| 4 |
MML Investors Services
Springfield,
Massachusetts
|
-$162K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$160K |
VRCA Hedge Fund Activity: Q2 2024 in Review
74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Verrica Pharmaceuticals (VRCA) for Q2 2024, worth a combined $136M — up 29% from $105M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VRCA positions and 9 closed out — a net gain of 14 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Propel Bio Management, opening a new position worth an estimated $3.26M. The largest seller was Fidelity Investments, cutting an estimated $3.08M.
- 74 institutional investors held Verrica Pharmaceuticals (VRCA) as of Q2 2024, up from 60 in Q1 2024.
- Funds reported $136M of Verrica Pharmaceuticals stock for Q2 2024, up 29% quarter-over-quarter.
- 23 funds opened new Verrica Pharmaceuticals positions in Q2 2024 and 9 closed out, a net change of +14 holders.
- The largest Verrica Pharmaceuticals buyer in Q2 2024 was Propel Bio Management, an estimated $3.26M added.
- The largest Verrica Pharmaceuticals seller in Q2 2024 was Fidelity Investments, an estimated $3.08M sold.
Based on aggregated 13F filings for Q2 2024.